LAE102 SC + Placebo SC + LAE102 IV + Placebo IV
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postmenopausal
Conditions
Postmenopausal, Healthy Adult Female Participants
Trial Timeline
Apr 22, 2025 → Oct 23, 2025
NCT ID
NCT06908707About LAE102 SC + Placebo SC + LAE102 IV + Placebo IV
LAE102 SC + Placebo SC + LAE102 IV + Placebo IV is a phase 1 stage product being developed by Eli Lilly for Postmenopausal. The current trial status is completed. This product is registered under clinical trial identifier NCT06908707. Target conditions include Postmenopausal, Healthy Adult Female Participants.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06908707 | Phase 1 | Completed |
Competing Products
20 competing products in Postmenopausal